目的比较不同碘水平下甲状腺结节患者与健康人血清外泌体微小核糖核酸(microRNA,miRNA)表达谱的差异,分析其共同点,为筛选不同碘水平下甲状腺结节早期诊断标志物提供参考依据。方法收集10例不同碘水平下甲状腺结节患者及体检健康者的外...目的比较不同碘水平下甲状腺结节患者与健康人血清外泌体微小核糖核酸(microRNA,miRNA)表达谱的差异,分析其共同点,为筛选不同碘水平下甲状腺结节早期诊断标志物提供参考依据。方法收集10例不同碘水平下甲状腺结节患者及体检健康者的外周血样本,采用砷铈催化分光光度法测定各组血清碘水平;提取外泌体miRNA,利用高通量测序技术测定血清miRNA的表达水平;预测差异靶基因,并进一步进行GO(Gene ontology)分析和KEGG(Kyoto Encyclopedia of Genes and Genomes)分析。结果在不同碘水平的甲状腺结节患者与健康人群中存在6个表达下调的miRNA,分别为miR-324-5p、miR-6511b-3p、miR-9903、miR-550a-3p、miR-5001-3p、miR-3688-3p。差异表达的外泌体miRNA可调控MAPK信号通路、PI3K-AKT信号通路、VEGF信号通路及NF-κB信号通路。结论筛选出6个差异表达miRNA,有望作为不同碘水平下甲状腺结节早期诊断的生物学标志物。展开更多
Since its approval by the Food and Drug Administration in 2011,transcatheter aortic valve implantation(TAVI)has rapidly evolved to become the preferred ultimate intervention for high-and intermediate-risk patients wit...Since its approval by the Food and Drug Administration in 2011,transcatheter aortic valve implantation(TAVI)has rapidly evolved to become the preferred ultimate intervention for high-and intermediate-risk patients with severe symptomatic aortic stenosis.[1]This is due to its non-open-heart,minimally invasive and off-pump advantages.[1]Nevertheless,as a result of the frequent frailty and comorbidity profiles of patients undergoing TAVI,such as advanced cardiac dysfunction and extensive coronary artery disease,or technically difficult anatomy for the procedure itself,[2-4]it is common for these patients to experience critical circulatory collapse perioperatively.These factors are linked to elevated mortality rates,necessitating suitable mechanical circulatory support(MCS)to reverse the disastrous situations.[5]展开更多
Background:With the decline of birth population and the development of medical technology in China,studies assessing how these changes have affected the adoption of congenital heart disease surgery at the national or ...Background:With the decline of birth population and the development of medical technology in China,studies assessing how these changes have affected the adoption of congenital heart disease surgery at the national or regional scale are lacking.Methods:We investigated the status of congenital heart surgery in China in the period from 2017-2022,through investigation of the total rates of cardiac surgeries,cardiopulmonary bypass(CPB),adult congenital heart surgeries(CHS),and pediatric CHS(<18 years old),as recorded by the Extracorporeal Cir-culation Branch of the Chinese Society of Biomedical Engineering.Subsequently,we evaluated correlations between these factors with economic,demographic,and other factors.Results:From 2017 to 2022,the total num-ber of cardiac operations increased from 230,772 to 263,292,representing an increase of 14.09%over 6 years;the CHS dropped from 76,365 to 68,940(10.19%decrease),and the proportion of CHS in the total cardiac surgeries dropped from 33.26%to 26.18%(7.08%decrease).Finally,cases of pediatric CHS decreased from 61,825 to 38,174(38.25%decrease).The annual percentage change(APC)of the total amount of pediatric CHS cases was-10.03(-15.95 to-3.69,p=0.013).Adult CHS increased from 14,940 to 30,766(105.93%increase).The proportion of adult CHS cases of the total number of cardiac surgeries increased from 6.47%to 11.68%(5.21%increase).From a regional perspective,the APC for the proportion of pediatric CHS in the local population was generally lower in western China.The proportion of CHS in the local population generally decreases from the north to the south,although the lowest incidence is found in the northeast region.Conclusions:Due to demographic changes,med-ical technology and economic factors,the number of surgical operations for congenital heart disease(CHD)in children decreased significantly from 2017 to 2022,and may decline further in the future.Nevertheless,in the same period,a significant increase in the number of operations for CHD in adults was observed,which brings new opportunities and challenges to the development of congenital cardiac surgery and cardiac critical care.展开更多
文摘目的比较不同碘水平下甲状腺结节患者与健康人血清外泌体微小核糖核酸(microRNA,miRNA)表达谱的差异,分析其共同点,为筛选不同碘水平下甲状腺结节早期诊断标志物提供参考依据。方法收集10例不同碘水平下甲状腺结节患者及体检健康者的外周血样本,采用砷铈催化分光光度法测定各组血清碘水平;提取外泌体miRNA,利用高通量测序技术测定血清miRNA的表达水平;预测差异靶基因,并进一步进行GO(Gene ontology)分析和KEGG(Kyoto Encyclopedia of Genes and Genomes)分析。结果在不同碘水平的甲状腺结节患者与健康人群中存在6个表达下调的miRNA,分别为miR-324-5p、miR-6511b-3p、miR-9903、miR-550a-3p、miR-5001-3p、miR-3688-3p。差异表达的外泌体miRNA可调控MAPK信号通路、PI3K-AKT信号通路、VEGF信号通路及NF-κB信号通路。结论筛选出6个差异表达miRNA,有望作为不同碘水平下甲状腺结节早期诊断的生物学标志物。
基金supported by the Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support(ZYLX202111,to XTH)Beijing Hospitals Authority“Ascent Plan”(FDL20190601,to XTH)+2 种基金Young Elite Scientists Sponsorship Program by CAST(2022QNRC001,to LSW)National Natural Science Foundation of China(82200433,to LSW)Beijing Hospitals Authority Youth Programme(QML20230602,to LSW).
文摘Since its approval by the Food and Drug Administration in 2011,transcatheter aortic valve implantation(TAVI)has rapidly evolved to become the preferred ultimate intervention for high-and intermediate-risk patients with severe symptomatic aortic stenosis.[1]This is due to its non-open-heart,minimally invasive and off-pump advantages.[1]Nevertheless,as a result of the frequent frailty and comorbidity profiles of patients undergoing TAVI,such as advanced cardiac dysfunction and extensive coronary artery disease,or technically difficult anatomy for the procedure itself,[2-4]it is common for these patients to experience critical circulatory collapse perioperatively.These factors are linked to elevated mortality rates,necessitating suitable mechanical circulatory support(MCS)to reverse the disastrous situations.[5]
文摘Background:With the decline of birth population and the development of medical technology in China,studies assessing how these changes have affected the adoption of congenital heart disease surgery at the national or regional scale are lacking.Methods:We investigated the status of congenital heart surgery in China in the period from 2017-2022,through investigation of the total rates of cardiac surgeries,cardiopulmonary bypass(CPB),adult congenital heart surgeries(CHS),and pediatric CHS(<18 years old),as recorded by the Extracorporeal Cir-culation Branch of the Chinese Society of Biomedical Engineering.Subsequently,we evaluated correlations between these factors with economic,demographic,and other factors.Results:From 2017 to 2022,the total num-ber of cardiac operations increased from 230,772 to 263,292,representing an increase of 14.09%over 6 years;the CHS dropped from 76,365 to 68,940(10.19%decrease),and the proportion of CHS in the total cardiac surgeries dropped from 33.26%to 26.18%(7.08%decrease).Finally,cases of pediatric CHS decreased from 61,825 to 38,174(38.25%decrease).The annual percentage change(APC)of the total amount of pediatric CHS cases was-10.03(-15.95 to-3.69,p=0.013).Adult CHS increased from 14,940 to 30,766(105.93%increase).The proportion of adult CHS cases of the total number of cardiac surgeries increased from 6.47%to 11.68%(5.21%increase).From a regional perspective,the APC for the proportion of pediatric CHS in the local population was generally lower in western China.The proportion of CHS in the local population generally decreases from the north to the south,although the lowest incidence is found in the northeast region.Conclusions:Due to demographic changes,med-ical technology and economic factors,the number of surgical operations for congenital heart disease(CHD)in children decreased significantly from 2017 to 2022,and may decline further in the future.Nevertheless,in the same period,a significant increase in the number of operations for CHD in adults was observed,which brings new opportunities and challenges to the development of congenital cardiac surgery and cardiac critical care.